Results 141 to 150 of about 5,304 (170)
Some of the next articles are maybe not open access.
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
BACKGROUNDWhether fixed-duration acalabrutinib-venetoclax (with or without obinutuzumab) would result in better progression-free survival than chemoimmunotherapy in patients with untreated chronic lymphocytic leukemia (CLL) is unknown.METHODSIn this ...
Daniel Lysak +2 more
exaly +4 more sources
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia [PDF]
Background Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL).
Anna Schuh, Peter Hillmen, John M Pagel
exaly +4 more sources
The efficacy and safety of acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, was evaluated in 2 phase 2 studies in hospitalized patients with coronavirus disease 2019 (COVID-19) who received acalabrutinib + best supportive care (BSC) versus BSC ...
Hans W. Prozesky +2 more
exaly +2 more sources
Analysis of Ventricular Arrhythmias and Sudden Death From Prospective, Randomized Clinical Trials of Acalabrutinib [PDF]
This analysis investigated the incidence of sudden deaths (SDs) and non-fatal and fatal ventricular arrhythmias (VAs) in five acalabrutinib clinical trials. In total, 1299 patients received acalabrutinib (exposure, 4568.4 patient-years).
Jeff P Sharman +2 more
exaly +3 more sources
EMA Review of Acalabrutinib for the Treatment of Adult Patients With Chronic Lymphocytic Leukemia
Oncologist, 2021Christian Gisselbrecht +2 more
exaly

